A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention

Immunomodulatory properties of histone deacetylase inhibitors represent a reasonable approach for acute graft-versus-host disease (aGVHD) prevention. We report a phase 2 trial evaluating panobinostat (PANO) administered over 26 weeks, starting on day −5 (5 mg orally 3 times a week) with tacrolimus i...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood Adv
Main Authors: Perez, Lia, Fernandez, Hugo, Kharfan-Dabaja, Mohamed, Khimani, Farhad, Betts, Brian, Mishra, Asmita, Ayala, Ernesto, Locke, Frederick L., Ochoa-Bayona, Leonel, Nieder, Michael, Pidala, Joseph, Achille, Alex, Powers, John, Sahakian, Eva, Thapa, Ram, Wang, Xuefeng, Anasetti, Claudio
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2021
Fag:
Transplantation
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8288668/
https://ncbi.nlm.nih.gov/pubmed/34242388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2021004225
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker